CXCL12 and breast carcinoma: These studies identified that the chemokine receptor, CXCR4 and its cognate ligand, CXCL12 were expressed in cancerous tissues and possibly modulated the migration and invasion of tumors in prostate, endometrial and breast cancer (26–29).